Actuate Therapeutics Inc
Veridion Score
Composite trend over time
Why is ACTU moving today?
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
Real vendor fields plus Veridion-computed history. Missing fields stay blank.
Warehouse intelligence for ACTU.
ACTU insider activity
Actuate Therapeutics Inc
No multi-insider buying cluster in the last 90 days
Net selling: -$652K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-02-13 | 2026-02-13 | SCHMITT DANIEL M | Insider | sell | $4.33 | 121,874 | 150,181 | $528K | SEC Form 4 |
| 2026-01-07 | 2026-01-05 | THOMSON TODD S | Insider | sell | $5.80 | 280,000 | 904,795 | $1.6M | SEC Form 4 |
| 2025-06-30 | 2025-06-27 | Bios Clinical Opportunity Fund, LP | Insider | buy | $7.00 | 71,428 | 196,428 | $500K | SEC Form 4 |
| 2025-06-30 | 2025-06-27 | BIOS Fund II NT, LP | Insider | buy | $7.00 | 71,428 | 196,428 | $500K | SEC Form 4 |
| 2025-06-30 | 2025-06-27 | BIOS Fund III, LP | Insider | buy | $7.00 | 71,428 | 196,428 | $500K | SEC Form 4 |
ACTU contract awards, year to date.
Public federal awards linked to this ticker.
ACTU lobbying filings, year to date.
Registered lobbying filings matched to Actuate Therapeutics Inc.